Minerva Neurosciences (NERV) Competitors $1.55 -0.02 (-1.27%) Closing price 03/11/2025 03:59 PM EasternExtended Trading$1.60 +0.04 (+2.90%) As of 03/11/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends NERV vs. OKYO, KALA, SPRO, FBLG, KZR, DYAI, MDCX, RNTX, ATRA, and LTRNShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include OKYO Pharma (OKYO), KALA BIO (KALA), Spero Therapeutics (SPRO), FibroBiologics (FBLG), Kezar Life Sciences (KZR), Dyadic International (DYAI), Medicus Pharma (MDCX), Rein Therapeutics (RNTX), Atara Biotherapeutics (ATRA), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. OKYO Pharma KALA BIO Spero Therapeutics FibroBiologics Kezar Life Sciences Dyadic International Medicus Pharma Rein Therapeutics Atara Biotherapeutics Lantern Pharma Minerva Neurosciences (NASDAQ:NERV) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Do analysts prefer NERV or OKYO? Minerva Neurosciences presently has a consensus price target of $5.00, suggesting a potential upside of 222.58%. OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 403.60%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in NERV or OKYO? Minerva Neurosciences received 337 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 56.42% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34756.42% Underperform Votes26843.58% OKYO PharmaOutperform Votes10100.00% Underperform VotesNo Votes Which has preferable earnings & valuation, NERV or OKYO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M$0.198.16OKYO PharmaN/AN/A-$16.83MN/AN/A Does the media prefer NERV or OKYO? In the previous week, OKYO Pharma had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for OKYO Pharma and 2 mentions for Minerva Neurosciences. OKYO Pharma's average media sentiment score of 0.36 beat Minerva Neurosciences' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OKYO Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in NERV or OKYO? 34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, NERV or OKYO? Minerva Neurosciences has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500. Is NERV or OKYO more profitable? Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% OKYO Pharma N/A N/A N/A SummaryOKYO Pharma beats Minerva Neurosciences on 9 of the 12 factors compared between the two stocks. Remove Ads Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.84M$7.00B$5.66B$7.98BDividend YieldN/A2.72%4.89%4.03%P/E Ratio-3.526.1923.8618.91Price / SalesN/A217.82382.37118.46Price / CashN/A65.6738.0534.62Price / Book-0.386.476.844.18Net Income-$30M$139.77M$3.19B$246.59M7 Day Performance-1.90%0.63%-0.48%-1.69%1 Month Performance-20.10%-6.51%-6.62%-8.83%1 Year Performance-44.84%-9.43%8.73%0.01% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences2.9875 of 5 stars$1.55-1.3%$5.00+222.6%-44.8%$10.98MN/A-3.529Analyst ForecastGap UpOKYOOKYO Pharma2.6812 of 5 stars$1.26+0.0%$7.00+455.6%-5.0%$42.63MN/A0.007Gap UpKALAKALA BIO3.4699 of 5 stars$6.99+0.9%$15.00+114.6%-13.0%$42.58M$3.89M-0.5630Gap DownSPROSpero Therapeutics4.5265 of 5 stars$0.77-0.7%$5.00+549.3%-57.6%$41.98M$89.87M11.00150FBLGFibroBiologics1.7169 of 5 stars$1.15-9.1%$13.00+1,035.4%-89.3%$41.69MN/A0.0010KZRKezar Life Sciences4.1 of 5 stars$5.70-0.2%$39.50+593.0%-39.7%$41.59M$7M-0.4360News CoverageDYAIDyadic International2.3233 of 5 stars$1.40-4.8%$6.00+328.6%-4.1%$41.43M$3.36M-6.097Positive NewsGap DownMDCXMedicus PharmaN/A$3.80-4.8%$10.00+163.2%N/A$41.22MN/A0.00N/AUpcoming EarningsGap DownHigh Trading VolumeRNTXRein TherapeuticsN/A$1.90-9.1%N/AN/A$41.17MN/A-0.619Positive NewsATRAAtara Biotherapeutics4.1473 of 5 stars$7.00+1.3%$17.75+153.6%-63.6%$40.32M$100.44M-0.27330Earnings ReportAnalyst ForecastLTRNLantern Pharma1.3765 of 5 stars$3.71-6.1%N/A-43.5%$40.01MN/A-2.0820Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies OKYO Pharma Alternatives KALA BIO Alternatives Spero Therapeutics Alternatives FibroBiologics Alternatives Kezar Life Sciences Alternatives Dyadic International Alternatives Medicus Pharma Alternatives Rein Therapeutics Alternatives Atara Biotherapeutics Alternatives Lantern Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NERV) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMarch 18th: Gold SHOCK? On March 18th, an event is taking place that could completely shock the market. Stocks could go ballistic…...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredMusk’s real agenda in Washington… In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
